MALVERN, Pa., Feb. 21, 2019 /PRNewswire/ -- Neuronetics, Inc. (NASDAQ:STIM) — NeuroStar® Advanced Therapy,
With more than 2.5 million treatments delivered to date, NeuroStar was the first TMS device to receive FDA clearance in 2008 as a safe and effective option for adult patients with Major Depressive Disorder (MDD). NeuroStar has become a trailblazer in the treatment of depression and offers hope to the 5.5 million adults in the U.S. with depression who do not see relief from antidepressant medication.,, Conference attendees will have a chance to hear from the TMS market leader about the latest research in the space, how to leverage data to improve patient outcomes and insights on best practices to maximize effective interactions with payers.
"Neuronetics remains committed to developing transformative technology, like NeuroStar Advanced Therapy, to improve the quality of life for patients," said Chris Thatcher, President and CEO of Neuronetics, Inc. "We're very proud of, and value, our relationship with the clinical community as we continually innovate to offer NeuroStar advancements and improvements, such as shortened treatment times and increased insurance coverage. Our partnership with the Clinical TMS Society allows us to work together to raise awareness of our life-changing treatments, giving patients their best chance for remission from depression."
NeuroStar will offer "Meet the Expert" sessions at booth #2 in the Exhibit Hall for attendees to learn about the latest TMS updates and best practices from Geoffrey Kanter, PhD, ABN, ABPdN, President, Comprehensive MedPsych Systems; Chung Trinh, President and CEO, Lighthouse Psychiatry TMS & Cuub Management; and W. Scott West, MD, Medical Director, ThriveLogic TMS + NeuroHealth, and Nashville NeuroCare Therapy.
NeuroStar will also host several educational symposia, including:
1. Is Your Patient Getting the Appropriate Stimulation? | Friday, February 22 | 7 a.m. NeuroStar is the only TMS system on the market that provides contact sensing technology to deliver the right dose to the right location every time to treat depression. Conference attendees can join the Breakfast Symposium to learn about practical perspectives and results of a new head-to-head study to assess whether patients are receiving the appropriate stimulation during treatment.
2. The Power of Big Data | Saturday, February 23 | 7:30 a.m. Greg Harper, Vice President of Product Development at NeuroStar, and Geoffrey Kanter, PhD, ABN, ABPdN, President at Comprehensive MedPsych Systems, will talk about the importance of data and how it can help physicians improve patient outcomes when it comes to TMS treatment. This session will also highlight advancements in NeuroStar's TrakStarTM technology, which is the only transcranial magnetic stimulation patient data management system that automatically tracks treatment information, patient history, and clinical outcomes, maximizing coordination of care.
3. Reimbursement Best Practices | Sunday, February 24 | 12 p.m. NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. There are also programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy. In this session, hear from NeuroStar experts and providers about reimbursement best practices to maximize success with payers.
Following the Clinical TMS Society Annual Meeting, NeuroStar will be a Platinum Sponsor at the 3rd Annual International Brain Stimulation Conference in Vancouver from February 24 – 27, 2019 at booth #103.
For more information about NeuroStar Advanced Therapy, visit www.NeuroStar.com.
About NeuroStar® Advanced TherapyNeuroStar® Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation. NeuroStar Advanced Therapy is the #1 TMS choice of doctors, and widely available across the United States.
NeuroStar is reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.
NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05). The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head.
NeuroStar® is a registered trademark of Neuronetics, Inc. (NASDAQ:STIM). For more information and full safety and prescribing information, visit www.neurostar.com.
1 Kessler RC, et al. JAMA, (2003)2 https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed 1/16/20183 Gaynes BN et al., Cleveland Clinic Journal of Medicine 2008;75(1):57-664 George MS, et al. Arch Gen Psychiatry, (2010)
View original content:http://www.prnewswire.com/news-releases/neurostar-advanced-therapy-to-host-industry-best-practices-symposia-at-clinical-tms-society-annual-meeting-300799294.html
SOURCE NeuroStar Advanced Therapy
Subscribe to our Free Newsletters!